CO2020005981A2 - Anticuerpos anti-tau y uso de los mismos - Google Patents
Anticuerpos anti-tau y uso de los mismosInfo
- Publication number
- CO2020005981A2 CO2020005981A2 CONC2020/0005981A CO2020005981A CO2020005981A2 CO 2020005981 A2 CO2020005981 A2 CO 2020005981A2 CO 2020005981 A CO2020005981 A CO 2020005981A CO 2020005981 A2 CO2020005981 A2 CO 2020005981A2
- Authority
- CO
- Colombia
- Prior art keywords
- tau antibodies
- antibodies
- tau
- methods
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona en la presente anticuerpos que enlazan específicamente Tau y métodos para usar los mismos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762572910P | 2017-10-16 | 2017-10-16 | |
US201762577011P | 2017-10-25 | 2017-10-25 | |
US201862697034P | 2018-07-12 | 2018-07-12 | |
PCT/IB2018/058024 WO2019077500A1 (en) | 2017-10-16 | 2018-10-16 | ANTI-WATER ANTIBODIES AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020005981A2 true CO2020005981A2 (es) | 2020-07-31 |
Family
ID=64100697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0005981A CO2020005981A2 (es) | 2017-10-16 | 2020-05-15 | Anticuerpos anti-tau y uso de los mismos |
Country Status (21)
Country | Link |
---|---|
US (4) | US10829547B2 (es) |
EP (1) | EP3697814A1 (es) |
JP (2) | JP6851549B2 (es) |
KR (2) | KR20200058480A (es) |
CN (1) | CN111630064B (es) |
AU (1) | AU2018352308B2 (es) |
BR (1) | BR112020007536A2 (es) |
CA (1) | CA3077247A1 (es) |
CL (3) | CL2020001003A1 (es) |
CO (1) | CO2020005981A2 (es) |
IL (2) | IL273832B (es) |
JO (1) | JOP20200074A1 (es) |
MA (1) | MA50397A (es) |
MX (1) | MX2020003857A (es) |
PE (2) | PE20210115A1 (es) |
PH (2) | PH12020551216A1 (es) |
SG (1) | SG11202003392VA (es) |
TW (3) | TWI853617B (es) |
UA (1) | UA129617C2 (es) |
WO (1) | WO2019077500A1 (es) |
ZA (1) | ZA202001548B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
EP3619233A4 (en) | 2017-05-02 | 2021-03-03 | Prothena Biosciences Limited | ANTIBODIES RECOGNIZING TAU PROTEIN |
JP6851549B2 (ja) * | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
WO2020180819A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
US12060434B2 (en) * | 2020-02-25 | 2024-08-13 | Gensun Biopharma Inc. | Trispecific T cell engagers |
US20220064271A1 (en) * | 2020-09-01 | 2022-03-03 | Washington University | Methods for treating tauopathies |
EP4222160A1 (en) * | 2020-10-02 | 2023-08-09 | Eli Lilly and Company | Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content |
KR20240033017A (ko) | 2021-07-09 | 2024-03-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 알츠하이머병 치료를 위한 바이오마커 |
CA3237660A1 (en) | 2021-11-03 | 2023-05-11 | Eisai R&D Management Co., Ltd. | Anti-tau antibody compositions, dosage forms, and methods |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023111618A1 (en) | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
JP2024547001A (ja) | 2021-12-17 | 2024-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 |
TW202339794A (zh) | 2022-02-02 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | 使用p—tau181水平之治療方法 |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
TW202430554A (zh) | 2022-11-28 | 2024-08-01 | 日商衛材R&D企管股份有限公司 | 使用tau PET水平之治療方法 |
WO2024254542A1 (en) | 2023-06-09 | 2024-12-12 | Eisai R&D Management Co., Ltd. | Methods of treatment using an anti-abeta protofibril antibody |
WO2025019457A1 (en) | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2025137359A1 (en) | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7982017B2 (en) | 2007-12-18 | 2011-07-19 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EA032675B1 (ru) | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Способ и композиции для лечения болезни альцгеймера и других таупатий |
US9304138B2 (en) | 2010-10-07 | 2016-04-05 | Katholieke Universiteit Leuven | Pharmaceutical composition |
HRP20181320T8 (hr) | 2010-10-11 | 2018-12-14 | Biogen International Neuroscience Gmbh | Ljudska anti-tau protutijela |
AU2012229222A1 (en) | 2011-03-11 | 2013-09-12 | Ramot At Tel-Aviv University Ltd. | Method for treating neurodegenerative tauopathy |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
CA2848346A1 (en) | 2011-09-19 | 2013-03-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP3578567A1 (en) | 2011-12-20 | 2019-12-11 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
EP2834270B1 (en) * | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
WO2013177104A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment for tauopathies |
WO2013180238A1 (ja) | 2012-05-31 | 2013-12-05 | 公立大学法人大阪市立大学 | 認知症治療剤又は予防剤 |
NZ703423A (en) * | 2012-07-03 | 2018-02-23 | Univ Washington | Antibodies to tau |
EP2885010B1 (en) | 2012-08-16 | 2020-01-01 | Ipierian, Inc. | Methods of treating a tauopathy |
US9650436B2 (en) | 2012-10-12 | 2017-05-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
WO2014089104A1 (en) | 2012-12-03 | 2014-06-12 | Washington University | Method for detection of aggregates in biological samples |
DK2935326T3 (da) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Humane anti-tau-antistoffer |
WO2014096321A1 (en) | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
CN105339002B (zh) | 2013-06-10 | 2019-06-28 | 伊皮埃里安股份有限公司 | 治疗tau病变的方法 |
GB201312226D0 (en) | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
EP3083680B1 (en) | 2013-12-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
JP6341274B2 (ja) | 2014-05-07 | 2018-06-13 | 株式会社村田製作所 | 弾性表面波装置 |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
CN107074965B (zh) | 2014-06-26 | 2021-08-03 | 扬森疫苗与预防公司 | 特异性结合微管相关蛋白tau的抗体和抗原结合片段 |
TW202136296A (zh) * | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
DE102014013571A1 (de) | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
PL3221349T3 (pl) | 2014-11-19 | 2021-05-17 | Axon Neuroscience Se | Humanizowane przeciwciała tau w chorobie Alzheimera |
WO2016086033A2 (en) | 2014-11-25 | 2016-06-02 | Abbott Diabetes Care Inc. | Analyte monitoring systems and related test and monitoring methods |
WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
WO2016137950A1 (en) | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對tau之抗體及其用途 |
IL300670B2 (en) | 2015-06-05 | 2025-02-01 | Genentech Inc | Anti-tau antibodies and methods of use |
CA2991451A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
AU2016289753C1 (en) | 2015-07-06 | 2021-08-05 | UCB Biopharma SRL | Tau-binding antibodies |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
US9704904B2 (en) * | 2015-08-27 | 2017-07-11 | Taiwan Semiconductor Manufacturing Company, Ltd. | Deep trench isolation structures and methods of forming same |
WO2017062496A2 (en) | 2015-10-05 | 2017-04-13 | University Of Virginia Patent Foundation | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer |
AU2016334051B2 (en) * | 2015-10-06 | 2023-10-26 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
CN116041504A (zh) | 2016-07-12 | 2023-05-02 | H.隆德贝克有限公司 | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
EP3619233A4 (en) * | 2017-05-02 | 2021-03-03 | Prothena Biosciences Limited | ANTIBODIES RECOGNIZING TAU PROTEIN |
JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
-
2018
- 2018-10-16 JP JP2020518723A patent/JP6851549B2/ja active Active
- 2018-10-16 EP EP18796772.4A patent/EP3697814A1/en active Pending
- 2018-10-16 PE PE2020000397A patent/PE20210115A1/es unknown
- 2018-10-16 US US16/161,586 patent/US10829547B2/en active Active
- 2018-10-16 BR BR112020007536-1A patent/BR112020007536A2/pt unknown
- 2018-10-16 SG SG11202003392VA patent/SG11202003392VA/en unknown
- 2018-10-16 CN CN201880066003.1A patent/CN111630064B/zh active Active
- 2018-10-16 TW TW112123476A patent/TWI853617B/zh active
- 2018-10-16 KR KR1020207011686A patent/KR20200058480A/ko not_active Ceased
- 2018-10-16 UA UAA202002730A patent/UA129617C2/uk unknown
- 2018-10-16 PH PH1/2020/551216A patent/PH12020551216A1/en unknown
- 2018-10-16 PE PE2021000519A patent/PE20212088A1/es unknown
- 2018-10-16 AU AU2018352308A patent/AU2018352308B2/en active Active
- 2018-10-16 WO PCT/IB2018/058024 patent/WO2019077500A1/en not_active Ceased
- 2018-10-16 TW TW107136326A patent/TWI750419B/zh active
- 2018-10-16 JO JOP/2020/0074A patent/JOP20200074A1/ar unknown
- 2018-10-16 CA CA3077247A patent/CA3077247A1/en active Pending
- 2018-10-16 TW TW110142156A patent/TWI809562B/zh active
- 2018-10-16 MX MX2020003857A patent/MX2020003857A/es unknown
- 2018-10-16 MA MA050397A patent/MA50397A/fr unknown
- 2018-10-16 KR KR1020207011600A patent/KR102225178B1/ko active Active
- 2018-12-12 US US16/217,360 patent/US10358485B2/en active Active
-
2020
- 2020-03-11 ZA ZA2020/01548A patent/ZA202001548B/en unknown
- 2020-04-06 IL IL273832A patent/IL273832B/en unknown
- 2020-04-08 PH PH12020550243A patent/PH12020550243A1/en unknown
- 2020-04-15 CL CL2020001003A patent/CL2020001003A1/es unknown
- 2020-05-15 CO CONC2020/0005981A patent/CO2020005981A2/es unknown
- 2020-09-24 US US17/030,655 patent/US11578120B2/en active Active
-
2021
- 2021-03-02 CL CL2021000517A patent/CL2021000517A1/es unknown
- 2021-03-02 CL CL2021000516A patent/CL2021000516A1/es unknown
- 2021-03-09 JP JP2021037603A patent/JP7223794B2/ja active Active
-
2022
- 2022-02-21 IL IL290783A patent/IL290783A/en unknown
-
2023
- 2023-01-04 US US18/149,905 patent/US20240034777A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020005981A2 (es) | Anticuerpos anti-tau y uso de los mismos | |
CL2019003114A1 (es) | Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063) | |
MX2024011869A (es) | Anticuerpos anti-tau y metodos de uso | |
CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CY1122653T1 (el) | Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων | |
ECSP19026178A (es) | Anticuerpos anti-pd-1 y sus usos | |
CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
BR112019012342A2 (pt) | anticorpos il-11 | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
MX2017007049A (es) | Anticuerpos anti-cd79b y métodos de uso. | |
CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
MX2019004690A (es) | Constructos de anticuerpos. | |
CL2022000087A1 (es) | Anticuerpo anti-tau y uso del mismo | |
MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
MX2017015817A (es) | Anticuerpos de union a tau. | |
CL2018001139A1 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos. | |
MX2018008302A (es) | Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. | |
MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
CR20200404A (es) | Anticuerpos anti-klk5 y métodos de uso |